Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07121972 · ClinicalTrials.gov registry record · NA

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

A NA study of Cancer Risk and Breast Cancer Risk, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
4
Study locations

NCT07121972: Recruiting NA study of Cancer Risk and Breast Cancer Risk, sponsored by University of California, San Francisco.

NCT07121972 is a NA study of Cancer Risk and Breast Cancer Risk that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 400 participants, below the 13,971-participant average among 7 other Cancer Risk trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07121972, a NA study of Cancer Risk and Breast Cancer Risk, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
4
Study locations

Study Summary

This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.

Primary Outcome

The CDR is defined as the number of breast cancers identified per 1,000 magnetic resonance imaging (MRI) screening examinations performed 1 year following supplemental screening MRI.

Interventions

  • PROCEDURE Magnetic resonance imaging (MRI)
  • DEVICE Artificial Intelligence (AI)

Study Locations (4)

California

  • University of California, San Diego - San Diego
  • University of California, San Francisco - San Francisco

Illinois

  • University of Chicago Comprehensive Cancer Center - Chicago

Massachusetts

  • University of Massachusetts Memorial Medical Center - Worcester

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-11-03
Est. Completion 2027-01-31
Phase NA

What NCT07121972 shows while recruiting

NCT07121972 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 13,971-participant average among 7 other Cancer Risk trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Cancer Risk appearing as the primary indexed condition, and to 2 interventions - of which Magnetic resonance imaging (MRI) is the first listed.

NCT07121972 reports a single indexed study location in California, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07121972 about?

NCT07121972 is a clinical study titled "Mirai-MRI: Validation of AI Models for Breast Cancer Risk". This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.

What is the current status of trial NCT07121972?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2025-11-03. Estimated completion is 2027-01-31.

What conditions does trial NCT07121972 study?

This clinical trial studies the following conditions: Cancer Risk, Breast Cancer Risk.

What interventions are being tested in trial NCT07121972?

The interventions under investigation include: Magnetic resonance imaging (MRI) (PROCEDURE), Artificial Intelligence (AI) (DEVICE).

Who is sponsoring clinical trial NCT07121972?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07121972 being conducted?

This trial has 4 study locations across California, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Risk

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07121972, the US trial registry maintained by the National Library of Medicine. NCT07121972 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.